Consolidative versus salvage stereotactic ablative radiotherapy to the primary lung tumor in stage IV non–small cell lung cancer - Takeaways - MDSpire

Consolidative versus salvage stereotactic ablative radiotherapy to the primary lung tumor in stage IV non–small cell lung cancer

  • By

  • Lisi Sun

  • Lulu Wang

  • Lina Yang

  • Wei Zhou

  • Yongzhong Wu

  • Dan Tao

  • July 15, 2026

Share

  • 1

    This study analyzed 90 patients with stage IV non-small cell lung cancer who received stereotactic ablative radiotherapy to the primary lung tumor.

  • 2

    Patients were divided into two groups: consolidative SABR (n=64) and salvage SABR (n=26), with comparable outcomes in local progression-free survival and overall survival.

  • 3

    Median follow-up was 38.8 months, showing no significant differences in local progression-free survival, distant metastasis-free survival, or overall survival between the two groups.

  • 4

    EGFR/ALK mutations were associated with improved local progression-free survival, distant metastasis-free survival, and overall survival in multivariable analysis.

  • 5

    Grade ≥2 radiation pneumonitis occurred in 12.2% of patients, with no significant difference in incidence between the consolidative and salvage SABR groups.

Original Source(s)

Consolidative versus salvage stereotactic ablative radiotherapy to the primary lung tumor in stage IV non–small cell lung cancer

  • by Lisi Sun, Lulu Wang, Lina Yang, Wei Zhou, Yongzhong Wu, Dan Tao

  • July 15, 2026

Related Content

Gut microbiota induces immune-related alterations in gene expression, RNA methylation, and metabolism in glioblastoma revealed by single-cell and spatial multi-omics

Surviving CGT's Funding Winter

In the first installment of a new series on the investment environment in cell and gene therapy, Circio CEO Erik Wiklund explains how he had to get creative to raise funds in a difficult biotech market

Case Report: Preoperative embolization for a large intracranial pheochromocytoma metastasis: a novel approach to minimize intraoperative risk